Free Trial

Design Therapeutics (DSGN) Competitors

Design Therapeutics logo
$6.35 +0.30 (+4.96%)
Closing price 04:00 PM Eastern
Extended Trading
$6.35 0.00 (0.00%)
As of 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DSGN vs. NTLA, TLRY, EVO, SNDX, STOK, AMPH, RCUS, PHVS, TRML, and GPCR

Should you be buying Design Therapeutics stock or one of its competitors? The main competitors of Design Therapeutics include Intellia Therapeutics (NTLA), Tilray Brands (TLRY), Evotec (EVO), Syndax Pharmaceuticals (SNDX), Stoke Therapeutics (STOK), Amphastar Pharmaceuticals (AMPH), Arcus Biosciences (RCUS), Pharvaris (PHVS), Tourmaline Bio (TRML), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry.

Design Therapeutics vs. Its Competitors

Intellia Therapeutics (NASDAQ:NTLA) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

Intellia Therapeutics has a beta of 2.28, suggesting that its stock price is 128% more volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500.

Design Therapeutics has lower revenue, but higher earnings than Intellia Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intellia Therapeutics$57.88M32.01-$519.02M-$4.69-3.68
Design TherapeuticsN/AN/A-$49.59M-$1.12-5.67

In the previous week, Intellia Therapeutics had 16 more articles in the media than Design Therapeutics. MarketBeat recorded 17 mentions for Intellia Therapeutics and 1 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 1.87 beat Intellia Therapeutics' score of 0.62 indicating that Design Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Intellia Therapeutics
4 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Design Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Intellia Therapeutics presently has a consensus price target of $27.39, indicating a potential upside of 58.68%. Given Intellia Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Intellia Therapeutics is more favorable than Design Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intellia Therapeutics
1 Sell rating(s)
7 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.53
Design Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 3.1% of Intellia Therapeutics shares are owned by company insiders. Comparatively, 23.5% of Design Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Design Therapeutics has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -908.48%. Design Therapeutics' return on equity of -27.15% beat Intellia Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Intellia Therapeutics-908.48% -57.48% -45.04%
Design Therapeutics N/A -27.15%-26.07%

Summary

Intellia Therapeutics beats Design Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Design Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DSGN vs. The Competition

MetricDesign TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$344.54M$3.16B$5.80B$10.46B
Dividend YieldN/A2.36%5.61%4.57%
P/E Ratio-5.6721.03348.5626.86
Price / SalesN/A447.99549.90125.65
Price / CashN/A44.8326.0131.15
Price / Book1.489.8315.536.50
Net Income-$49.59M-$52.82M$3.29B$271.25M
7 Day Performance8.36%3.47%200.87%3.69%
1 Month Performance20.72%5.35%184.38%8.07%
1 Year Performance7.99%13.26%325.51%29.65%

Design Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DSGN
Design Therapeutics
0.3125 of 5 stars
$6.35
+5.0%
N/A+2.9%$344.54MN/A-5.6740Positive News
NTLA
Intellia Therapeutics
4.4528 of 5 stars
$12.35
+6.7%
$27.11
+119.6%
-28.7%$1.33B$52.86M-2.64600Analyst Forecast
TLRY
Tilray Brands
2.8088 of 5 stars
$1.21
+2.1%
$1.94
+60.8%
-29.7%$1.33B$210.48M-0.522,842
EVO
Evotec
1.7545 of 5 stars
$3.68
+5.1%
$5.40
+46.7%
+7.4%$1.31B$777.33M0.004,827
SNDX
Syndax Pharmaceuticals
3.8324 of 5 stars
$15.03
-5.1%
$39.22
+160.9%
-19.1%$1.30B$23.68M-3.87110Analyst Forecast
STOK
Stoke Therapeutics
3.7634 of 5 stars
$23.33
-0.3%
$25.57
+9.6%
+66.5%$1.28B$199.89M27.38100Positive News
AMPH
Amphastar Pharmaceuticals
4.0039 of 5 stars
$27.15
-0.4%
$31.60
+16.4%
-43.8%$1.26B$731.97M10.182,028Positive News
RCUS
Arcus Biosciences
1.927 of 5 stars
$11.73
+1.3%
$21.14
+80.3%
-24.8%$1.25B$262M-3.70500Positive News
PHVS
Pharvaris
2.4425 of 5 stars
$23.62
+1.0%
$34.00
+43.9%
+30.0%$1.24BN/A-7.0430Gap Up
TRML
Tourmaline Bio
0.8672 of 5 stars
$47.70
+0.1%
$45.65
-4.3%
+107.3%$1.23BN/A-13.9144
GPCR
Structure Therapeutics
2.9491 of 5 stars
$21.27
+5.3%
$75.71
+256.0%
-43.8%$1.23BN/A-20.26136Gap Up

Related Companies and Tools


This page (NASDAQ:DSGN) was last updated on 9/22/2025 by MarketBeat.com Staff
From Our Partners